Harrow (HROW) Capital Expenditures (2012 - 2026)
Harrow's (HROW) quarterly Capital Expenditures came in at $194000.0 in Q1 2026, up 14.12% year-on-year from $170000.0 in Q1 2025, and down 43.11% quarter-over-quarter from $341000.0 in Q4 2025.
Harrow (HROW) Capital Expenditures (2012 - 2026) Analysis & Trends
Harrow's Capital Expenditures history runs 15 years deep, the most recent figure standing at $194000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 14.12% year-over-year to $194000.0 in Q1 2026; TTM through Mar 2026 was $911000.0, a 45.64% decrease from a year earlier, with the FY2025 full-year figure at $887000.0, down 44.39% from the prior year.
- Capital Expenditures eased to $194000.0 in Q1 2026 per HROW's latest filing, from $341000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.4 million in Q4 2024 and bottomed at -$381000.0 in Q2 2023.
- The 5-year median for Capital Expenditures is $260000.0 (2022), against an average of $396058.8.
- Across the five-year window, Capital Expenditures tumbled 246.54% in 2023 and jumped 630.93% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at $878000.0 in 2022, then sank by 77.9% to $194000.0 in 2023, then soared by 630.93% to $1.4 million in 2024, then plunged by 75.95% to $341000.0 in 2025, then sank by 43.11% to $194000.0 in 2026.
- Per Business Quant, the three latest HROW Capital Expenditures figures stand at $194000.0 (Q1 2026), $341000.0 (Q4 2025), and $416000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 194,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 194,000.00 |
| Mar 31, 2026 | 194,000.00 |
| Dec 31, 2025 | 341,000.00 |
| Dec 31, 2025 | 341,000.00 |
| Sep 30, 2025 | 416,000.00 |
| Sep 30, 2025 | 416,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | 1.42 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 133,000.00 |
| Sep 30, 2024 | 133,000.00 |
| Jun 30, 2024 | -45,000.00 |
| Jun 30, 2024 | -45,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Dec 31, 2023 | 194,000.00 |
| Dec 31, 2023 | 194,000.00 |